In recent trading session, Bristol-Myers Squibb Co. (NYSE:BMY) saw 4.79 million shares changing hands at last check today with its beta currently measuring 0.46. Company’s recent per share price level of $50.99 trading at $0.87 or 1.73% at last check today assigns it a market valuation of $103.37B. That most recent trading price of BMY’s stock is at a discount of -15.22% from its 52-week high price of $58.75 and is indicating a premium of 22.83% from its 52-week low price of $39.35. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 12.49 million shares which gives us an average trading volume of 13.65 million if we extend that period to 3-months.
For Bristol-Myers Squibb Co. (BMY), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 2.89. Splitting up the data highlights that, out of 14 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 9 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 1.59 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bristol-Myers Squibb Co. (NYSE:BMY) trade information
Upright in the green today for gaining 1.73%, in the last five days BMY remained trading in the green while hitting it’s week-highest on Friday, 09/27/24 when the stock touched $50.99 price level, adding 2.24% to its value on the day. Bristol-Myers Squibb Co.’s shares saw a change of -0.63% in year-to-date performance and have moved 3.19% in past 5-day. Bristol-Myers Squibb Co. (NYSE:BMY) showed a performance of 3.92% in past 30-days. Number of shares sold short was 21.79 million shares which calculate 2.28 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 66.5 to the stock, which implies a rise of 23.32% to its recent value today. Analysts have been projecting 41 as a low price target for the stock while placing it at a high target of 85. It follows that stock’s current price would jump 19.59% in reaching the projected high whereas dropping to the targeted low would mean a gain of 19.59% for stock’s current value.
Bristol-Myers Squibb Co. (BMY) estimates and forecasts
Statistics highlight that Bristol-Myers Squibb Co. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -5.98% of value to its shares in past 6 months, showing an annual growth rate of -89.75% while that of industry is 17.70. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 11.30% from the last financial year’s standing.
16 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 11.3B for the same. And 15 analysts are in estimates of company making revenue of 11.48B in the next quarter. Company posted 9.99B and 10.72B of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 5.14% during past 5 years. In 2024, company’s earnings growth rate is likely to be around -90.06% while estimates for its earnings growth in next 5 years are of -4.81%.
BMY Dividends
Bristol-Myers Squibb Co. is more likely to be releasing its next quarterly report on 2024-Oct-31 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt. With an annual yield of 4.65%, the share has a forward dividend of 2.37 which implies that company’s dividend yield remained growing in trailing twelve months while having a 5 year average dividend yield of 3.36%.
Bristol-Myers Squibb Co. (NYSE:BMY)’s Major holders
Insiders are in possession of 0.11% of company’s total shares while institution are holding 78.03 percent of that, with stock having share float percentage of 78.11%. Investors also watch the number of corporate investors in a company very closely, which is 78.03% institutions for Bristol-Myers Squibb Co. that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at BMY for having 186.57 million shares of worth $7.75 billion. And as of 2024-06-30, it was holding 9.2225 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 158.66 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.8428 of outstanding shares, having a total worth of $6.59 billion.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024, the former fund manager was holding 64.14 shares of worth $3.27 billion or 3.16% of the total outstanding shares. The later fund manager was in possession of 52.03 shares on Jun 30, 2024, making its stake of worth around $2.65 billion in the company or a holder of 2.57% of company’s stock.
